Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial by Burmester, Gerd R. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-07-01 
Tocilizumab combination therapy or monotherapy or 
methotrexate monotherapy in methotrexate-naive patients with 
early rheumatoid arthritis: 2-year clinical and radiographic results 
from the randomised, placebo-controlled FUNCTION trial 
Gerd R. Burmester 
Charite-Universitatsmedizin Berlin 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Musculoskeletal Diseases Commons, and the Rheumatology Commons 
Repository Citation 
Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S. 
(2017). Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-
naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the 
randomised, placebo-controlled FUNCTION trial. Open Access Articles. https://doi.org/10.1136/
annrheumdis-2016-210561. Retrieved from https://escholarship.umassmed.edu/oapubs/3133 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
CONCISE REPORT
Tocilizumab combination therapy or monotherapy
or methotrexate monotherapy in methotrexate-naive
patients with early rheumatoid arthritis: 2-year
clinical and radiographic results from the
randomised, placebo-controlled FUNCTION trial
Gerd R Burmester,1 William F Rigby,2 Ronald F van Vollenhoven,3,4 Jonathan Kay,5
Andrea Rubbert-Roth,6 Ricardo Blanco,7 Alysha Kadva,8 Sophie Dimonaco9
ABSTRACT
Objective Investigate whether the efﬁcacy and safety
of intravenous tocilizumab (TCZ) demonstrated at week
52 in patients with early rheumatoid arthritis (RA) are
maintained to week 104.
Methods Methotrexate (MTX)-naive patients with early
progressive RA were randomly assigned to double-blind
4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ
+placebo or placebo+MTX for 104 weeks. Patients not
receiving 8 mg/kg TCZ and not achieving Disease Activity
Score-28 joints (DAS28-erythrocyte sedimentation rate
(ESR)) ≤3.2 at week 52 switched to escape therapy
(8 mg/kg TCZ+MTX). Analyses were exploratory.
Results Intent-to-treat and safety populations included
1157 and 1153 patients, respectively. DAS28-ESR
remission (<2.6) rates were maintained from weeks 52 to
104 (eg, 8 mg/kg TCZ+MTX, 49.3% to 47.6%). Placebo
+MTX and 4 mg/kg TCZ+MTX escape patients’ week 104
response rates were 51.4% and 30.5%, respectively.
Inhibition of radiographic progression was maintained with
8 mg/kg TCZ (eg, 8 mg/kg TCZ+MTX mean (SD) change
from baseline in modiﬁed total Sharp score: 0.13 (1.28),
week 52; 0.19 (2.08), week 104). The safety proﬁle of TCZ
was consistent with that of previous reports.
Conclusions Patients with early RA treated with TCZ
monotherapy or TCZ+MTX maintained clinical beneﬁts
during their second year of treatment with no new safety
signals.
Trial registration number: NCT01007435.
INTRODUCTION
Early intensive treatment, including addition of a
biological agent to conventional synthetic disease-
modifying antirheumatic drugs (DMARDs), is
recommended for patients with rheumatoid arth-
ritis (RA) and features of poor prognosis.1 2
Tocilizumab (TCZ), an interleukin-6 receptor-alpha
inhibitor, has demonstrated safety and efﬁcacy in
combination with DMARDs in patients with RA
and inadequate response to DMARDs3–6 and as
monotherapy in patients with RA.7–9 The multicen-
tre, 2-year, double-blind, double-dummy, rando-
mised, parallel-group, phase III FUNCTION trial
investigated the efﬁcacy and safety of TCZ in com-
bination with methotrexate (MTX) and as mono-
therapy in patients with early, active, progressive
RA who were MTX-naive.10 The week 52 analysis
showed that compared with MTX, TCZ+MTX or
TCZ signiﬁcantly improved rates of remission
according to Disease Activity Score based on 28
joint counts and erythrocyte sedimentation rate
(DAS28-ESR <2.6). TCZ+MTX also inhibited
joint damage progression and improved physical
function at 52 weeks compared with MTX.10
This analysis investigated whether previously
reported clinical beneﬁts and safety proﬁles of TCZ
were maintained through 104 weeks of double-
blind treatment.
PATIENTS AND METHODS
Patient populations and methods of this trial have
been described.10 Brieﬂy, MTX-naive patients
(≥18 years old) with moderate to severe, active,11
early (≤2 years) RA were randomly assigned
(1:1:1:1) to 8 mg/kg TCZ+MTX, 4 mg/kg TCZ
+MTX, 8 mg/kg TCZ+placebo (TCZ monother-
apy) or placebo+MTX. TCZ+placebo was admi-
nistered intravenously every four weeks. MTX was
administered as oral capsules starting at 7.5 mg/
week to a maximum of 20 mg/week at week 8 if
they had swollen or tender joints (see online
supplementary appendix table S1 for mean MTX
doses). Randomisation was stratiﬁed by serological
status (presence of rheumatoid factor (RF) and/or
anticyclic citrullinated peptide (anti-CCP) anti-
bodies) and geographical region.
Inclusion criteria included DAS28-ESR >3.2, ESR
≥28 mm/h or C reactive protein (CRP) ≥1 mg/dL,
seropositivity for RF or anti-CCP antibodies and
RA-associated erosion in ≥1 joint. Data were col-
lected until the end of the double-blind treatment
(week 104) and the 8-week safety follow-up. At week
52, patients receiving 4 mg/kg TCZ+MTX or
placebo+MTX who had not achieved low disease
activity (LDA; DAS28-ESR ≤3.2) were switched to
8 mg/kg TCZ+MTX (escape therapy) and analysed
under their originally assigned treatment groups in a
separate postescape subanalysis, re-baselined at the
time of escape.
Assessments
Efﬁcacy was assessed in the intent-to-treat (ITT)
population (randomly assigned patients who
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received ≥1 dose of TCZ/placebo) by evaluating DAS28-ESR
remission (<2.6) and LDA; American College of Rheumatology
(ACR)20/50/70 responses; Clinical Disease Activity Index
(CDAI) remission (<2.8); ACR/European League Against
Rheumatism (EULAR) Boolean remission (tender joint count
(68) ≤1, swollen joint count (66) ≤1, Patient Global Assessment
of Disease Activity visual analogue scale (VAS, cm) ≤1 and CRP
≤1 mg/dL) and index remission (Simpliﬁed Disease Activity
Index (SDAI) ≤3.3); radiographic measures (van der Heijde–
modiﬁed total Sharp score (vdH mTSS), erosion score and
joint space narrowing score). Baseline and week 52 radiographs
were reread by the joint assessor along with the week 104
radiographs; a baseline radiograph and at least one postbaseline
time point had to be available for a patient to be included in
the analysis. The study used two assessors, but a third assessor
adjudicated in cases where scores did not match. All X-rays were
blinded to order and treatment group. Serum TCZ levels and
neutralising anti-TCZ antibodies were measured regularly
through week 104, including withdrawal (see online
supplementary appendix).
Safety was assessed in the safety population (all patients who
received ≥1 TCZ+placebo infusion and had ≥1 postdose safety
assessment). Adverse events (AEs) and serious AEs (SAEs) were
reported. All analyses were exploratory; no statistical analyses
were performed to compare treatment arms at week 104.
RESULTS
Patients
Of 1162 randomly assigned patients, 1157 were included in the
ITT population and 1153 in the safety population; 809 (69.6%)
completed week 104 (see online supplementary appendix
ﬁgure S1). At week 52, 33% (95/290) of patients receiving 4 mg/kg
TCZ+MTX and 49% (142/289) receiving placebo+MTX
switched to escape therapy with 8 mg/kg TCZ+MTX.
Demographics and disease characteristics at baseline were similar
across treatment arms in the ITT population10 and in escape
patients (see online supplementary appendix table S2).
Efﬁcacy
DAS28-ESR remission rates were maintained from weeks 52
through 104 (ﬁgure 1A). DAS28-ESR remission was achieved by
49.3% (143/290) of patients in the 8 mg/kg TCZ+MTX group
at week 52 and by 47.6% (138/290) at week 104, and
DAS28-ESR LDA was achieved by 57.9% (168/290) and 55.5%
(161/290), respectively (ﬁgure 1A). Proportions of patients who
lost DAS28-ESR LDA (DAS28-ESR >3.2 at two consecutive
visits) after week 52 were 4.2% (7/168) in the 8 mg/kg TCZ
+MTX group and 4.8% (7/147) in the 8 mg/kg TCZ monother-
apy group. Proportions of patients achieving ACR20, ACR50
and ACR70 responses were similar at weeks 52 and 104 in the
8 mg/kg TCZ monotherapy and 8 mg/kg TCZ+MTX groups
(ﬁgure 1B). After 52 weeks of escape therapy, 30.5% (29/95)
and 51.4% (73/142) of patients who originally received 4 mg/kg
TCZ+MTX and placebo+MTX, respectively, achieved
DAS28-ESR remission (ﬁgure 1A). ACR20, ACR50 and ACR70
response rates after 52 weeks of escape therapy were 43.0%,
30.3% and 16.2%, respectively, in the placebo+MTX escape
group and 29.5%, 16.8% and 6.3%, respectively, in the 4 mg/kg
TCZ+MTX escape group (ﬁgure 1B). Similar proportions of
patients in each initial treatment arm achieved remission accord-
ing to CDAI and ACR/EULAR Boolean and Index criteria at
weeks 52 and 104 (ﬁgure 1C).
Inhibition of radiographic progression was maintained
between weeks 52 and 104 for both 8 mg/kg TCZ groups and
was numerically greater in the 8 mg/kg TCZ+MTX group. The
mean (SD) change from baseline in vdH mTSS was 0.13 (1.28)
at week 52 and 0.19 (2.08) at week 104 for the 8 mg/kg TCZ
+MTX group (table 1). The annualised progression rate (APR)
for vdH mTSS was numerically lower for the TCZ groups than
the placebo+MTX group in the ﬁrst and second years and
between baseline and week 104. The vdH mTSS APR decreased
in patients who switched to escape therapy (see online
supplementary appendix table S3).
Post hoc analysis of efﬁcacy at week 104 according to achieve-
ment of DAS28-ESR LDA at week 52 suggested that in the TCZ
groups some week 52 non-responders achieved responses at
week 104; for example, 14–17% of week 52 LDA non-
responders achieved remission at week 104 (see online
supplementary appendix table S4).
Pharmacokinetics
Mean predose serum TCZ concentrations over time were
similar for both 8 mg/kg TCZ groups (see online supplementary
appendix ﬁgure S2).
Safety
Eighty-three SAEs were reported in the 8 mg/kg TCZ+MTX
group compared with 67, 58 and 31 for the 8 mg/kg TCZ
+placebo, 4 mg/kg TCZ+MTX and placebo+MTX groups,
respectively (table 2). Rates (95% CI) of SAEs per 100
patient-years (PY) were 11.6 (9.2 to 14.3), 13.3 (10.3 to
16.9), 14.7 (11.2 to 19.0) and 9.1 (6.2 to 13.0), respectively.
Most AEs were mild or moderate in intensity (96–97% across
the four treatment groups). Infections were the most fre-
quently reported AEs/SAEs in all treatment arms, with AE
rates (95% CI) per 100 PY ranging from 89.4 (82.6–96.6) for
8 mg/kg TCZ+MTX to 113.3 (103.0–124.3) for 4 mg/kg
TCZ+MTX.
Fourteen deaths occurred during the study: nine in the ﬁrst
year10 and ﬁve in the second year (none on escape therapy).
Causes of second-year deaths included duodenal ulcer haemor-
rhage in a patient receiving 4 mg/kg TCZ+MTX, interstitial lung
disease and endometrial cancer in patients receiving 8 mg/kg TCZ
+MTX and congestive heart failure and metastatic cancer in
patients receiving 8 mg/kg TCZ+placebo (see online
supplementary appendix table S5). Switching to escape therapy
did not impact the incidence or rate of AEs (see online
supplementary appendix table S6).
Immunogenicity
Nine patients tested positive for neutralising anti-TCZ anti-
bodies (8 mg/kg TCZ+MTX, n=2; 8 mg/kg TCZ+placebo,
n=2; 4 mg/kg TCZ+MTX, n=5), though none withdrew from
treatment because of insufﬁcient therapeutic responses.
DISCUSSION
FUNCTION is the ﬁrst study of TCZ initiated in patients with
early RA. Year 2 results show that the efﬁcacy of TCZ10 was
maintained for extended treatment periods; patients with early
RA who received 8 mg/kg TCZ+MTX or 8 mg/kg TCZ mono-
therapy exhibited sustained improvement in disease activity and
maintained inhibition of joint damage during their second year
of treatment. In both 8 mg/kg TCZ groups, week 52 improve-
ments were maintained through week 104 for DAS28-ESR
remission and LDA, ACR 20/50/70 responses and radiographic
progression. The best responses were consistently observed in
the 8 mg/kg TCZ+MTX group, particularly for radiographic
endpoints. Maintenance of response with 8 mg/kg TCZ
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monotherapy suggests that early TCZ therapy is a viable option
for patients intolerant of MTX. Some patients in the TCZ
groups who did not achieve DAS28-ESR LDA by week 52
achieved remission by week 104 in a post hoc analysis, suggest-
ing that longer treatment may be required to observe efﬁcacy in
some patients.
In escape patients who received 4 mg/kg TCZ+MTX or
placebo+MTX in the ﬁrst year and 8 mg/kg TCZ+MTX in the
second year, further efﬁcacy improvements were generally
observed from escape through week 104 for DAS28-ESR, ACR
and radiographic endpoints. Although comparable DAS28-ESR
remission rates were observed between escape patients who
Figure 1 Proportions of patients
achieving (A) Disease Activity Score
based on 28 joint counts and
erythrocyte sedimentation rate
(DAS28-ESR) remission or low disease
activity (LDA), (B) ACR20/50/70
responses at weeks 52 and 104 or (C)
Clinical Disease Activity Index (CDAI)
remission, American College of
Rheumatology (ACR)/European League
Against Rheumatism (EULAR) Boolean
remission or ACR/EULAR Index
remission (intent-to-treat (ITT)
population). For DAS28 and ACR, last
observation carried forward (LOCF) was
used for missing tender and swollen
joint counts. No imputation was used
for missing ESR, Patient Global
Assessment of Disease Activity visual
analogue scale, Health Assessment
Questionnaire–Disability Index score or
C reactive protein (CRP). ESR was used
if CRP was missing for assessment of
ACR response. For CDAI, data collected
after withdrawal or initiation of escape
therapy were set to missing, and LOCF
was used for missing data. Patients
who received escape therapy or
withdrew prematurely or for whom a
DAS28 score, ACR response or EULAR
response could not be calculated were
considered non-responders. Postescape
data at week 104 were based on the
postescape baseline and represented
52 weeks of 8 mg/kg tocilizumab (TCZ)
+ methotrexate (MTX) escape therapy.
SDAI, Simpliﬁed Disease Activity Index.
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Table 1 Radiographic endpoints (intent-to-treat population)
Time point
Placebo
+MTX
n=287
4 mg/kg TCZ
+MTX
n=288
8 mg/kg TCZ
+MTX
n=290
8 mg/kg TCZ
+placebo
n=292
vdH mTSS,* mean (SD) change from baseline Week 52 0.97 (3.207) 0.75 (5.901) 0.13 (1.278) 0.30 (2.699)
Week 104 1.88 (6.242) 1.43 (11.669) 0.19 (2.081) 0.62 (4.756)
Erosion score,* mean (SD) change from baseline Week 52 0.52 (2.075) 0.30 (2.061) 0.09 (0.878) 0.08 (1.318)
Week 104 1.01 (4.040) 0.57 (4.062) 0.11 (1.341) 0.19 (1.974)
JSN score,* mean (SD) change from baseline Week 52 0.45 (1.697) 0.45 (4.024) 0.04 (0.705) 0.22 (2.120)
Week 104 0.87 (3.284) 0.86 (7.958) 0.08 (1.175) 0.43 (3.981)
APR for vdH mTSS,† mean (SD) Baseline to week
52
0.87 (2.706) 0.33 (1.618) 0.09 (0.894) 0.14 (1.370)
Weeks 52–104 0.23 (0.762) 0.12 (0.813) 0.00 (0.621) 0.13 (0.776)
Patients with no progression of vdH mTSS, n/N (%) Week 52 190/266 (71) 205/266 (77) 231/272 (85) 224/275 (81)
Week 104 180/266 (68) 194/266 (73) 227/272 (83) 219/275 (80)
Percentage inhibition of vdH mTSS change from baseline compared with
placebo+MTX
Week 104 – 23.94 89.89 67.02
*Data collected after withdrawal or initiation of escape therapy was set to missing; missing data were imputed using linear extrapolation.
†Observed data.
APR, annualised progression rate; JSN, joint space narrowing; MTX, methotrexate; TCZ, tocilizumab; vdH mTSS, van der Heijde–modified total Sharp score.
Table 2 Safety at week 104 (safety population)
Placebo+MTX
n=282
4 mg/kg TCZ+MTX
n=289
8 mg/kg TCZ+MTX
n=527
8 mg/kg TCZ+placebo
n=292
Exposure, PY 339.53 394.64 718.39 502.26
AEs, rate/100 PY (95% CI) (events, n)
Overall AEs 367.9
(347.7 to 388.8)
(1249)
391.5
(372.2 to 411.5)
(1545)
336.6
(323.3 to 350.3)
(2418)
338.7
(322.8 to 355.2)
(1701)
Withdrawal due to AE 6.5
(4.1 to 9.8)
(22)
9.9
(7.0 to 13.5)
(39)
12.0
(9.6 to 14.8)
(86)
10.0
(7.4 to 13.1)
(50)
Overall SAEs 9.1
(6.2 to 13.0)
(31)
14.7
(11.2 to 19.0)
(58)
11.6
(9.2 to 14.3)
(83)
13.3
(10.3 to 16.9)
(67)
Deaths 0.59
(0.07 to 2.13)
(2)
1.27
(0.41 to 2.96)
(5)
0.56
(0.15 to 1.43)
(4)
0.60
(0.12 to 1.75)
(3)
AEs of special interest, rate/100 PY (95% CI) (events, n)
Infection AEs* 98.1
(87.8 to 109.2)
(333)
113.3
(103.0 to 124.3)
(447)
89.4
(82.6 to 96.6)
(642)
94.4
(86.1 to 103.3)(474)
Infection SAEs* 1.8
(0.6 to 3.8)
(6)
4.1
(2.3 to 6.6)
(16)
3.5
(2.3 to 5.1)
(25)
4.0
(2.4 to 6.1)
(20)
Malignancy SAEs 0.9
(0.2 to 2.6)
(3)
1.0
(0.3 to 2.6)
(4)
0.4
(0.1 to 1.2)
(3)
1.0
(0.3 to 2.3)
(5)
Stroke SAEs 0.6
(0.1 to 2.1)
(2)
0.8
(0.2 to 2.2)
(3)
0.4
(0.1 to 1.2)
(3)
0.2
(0.0 to 1.1)
(1)
Myocardial infarction SAEs 0.0
(0.0 to 1.1)
(0)
0.8
(0.2 to 2.2)
(3)
0.3
(0.0 to 1.0)
(2)
0.2
(0.0 to 1.1)
(1)
GI perforation SAEs† 0.3
(0.0 to 1.6)
(1)
0.0
(0.0 to 0.9)
(0)
0.0
(0.0 to 0.5)
(0)
0.2
(0.0 to 1.1)
(1)
Hepatic SAEs‡ 0.0
(0.0 to 1.1)
(0)
0.0
(0.0 to 0.9)
(0)
0.0
(0.0 to 0.5)
(0)
0.0
(0.0 to 0.7)
(0)
Continued
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received 8 mg/kg TCZ+MTX in the second year and patients
who received 8 mg/kg TCZ+MTX throughout, ACR response
rates were lower and the overall degree of joint damage was
greater in escape patients, highlighting the importance of early
initiation of therapy.
Improvements in the placebo+MTX escape group were com-
parable to those of patients receiving 8 mg/kg TCZ throughout.
Serum TCZ concentrations were maintained at similar levels
between the 8 mg/kg TCZ+placebo and 8 mg/kg TCZ+MTX
groups, indicating that, in contrast to adalimumab,12 MTX does
not appear to have an additive effect on serum drug levels. Only
nine patients tested positive for neutralising anti-TCZ anti-
bodies, none of whom withdrew because of insufﬁcient thera-
peutic response or loss of efﬁcacy, consistent with previous
reports.13
Because of the complexity of multiple comparisons, all week
104 analyses were exploratory, which is a limitation of this
study. Post-week 52 data for the 4 mg/kg TCZ+MTX and
placebo+MTX groups should be interpreted with caution given
the large number of patients switching to escape therapy. This
meant the data were enriched for patients who achieved DAS28
LDA at week 52 for endpoints at which escape patients were set
to missing and possibly underestimated for endpoints at which
they were considered non-responders.
The most common AEs/SAEs in all groups were infections.
Although there was no clear difference in the rate of infections
between the TCZ and placebo+MTX groups, the rate of serious
infections was numerically higher with TCZ (95% CIs overlap-
ping). Rates of infection and serious infection did not appear to
increase over time. Safety was consistent with the known TCZ
safety proﬁle. The low incidence of gastrointestinal perforations
may reﬂect less exposure to non-steroidal anti-inﬂammatory
drugs and corticosteroids. No new safety signals were identiﬁed
in this MTX-naive patient population with early RA.
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Table 2 Continued
Placebo+MTX
n=282
4 mg/kg TCZ+MTX
n=289
8 mg/kg TCZ+MTX
n=527
8 mg/kg TCZ+placebo
n=292
Clinical laboratory abnormalities, n (%)
Neutropenia
Grade 3
<1.0–0.5×109/L
1 (0.4) 3 (1.0) 21 (4.0) 14 (4.8)
Grade 4
<0.5×109/L
0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Thrombocytopenia (based on platelet count)
Grade 3
<50–25×109/L
1 (0.4) 1 (0.3) 0 (0.0) 1 (0.3)
Grade 4
<25×109/L
1 (0.4) 0 (0.0) 1 (0.2) 0 (0.0)
ALT elevations
Grade 1
>ULN-2.5× ULN
122 (43.3) 133 (46.2) 261 (49.7) 138 (47.3)
Grade 2
>2.5–5× ULN
25 (8.9) 38 (13.2) 101 (19.2) 27 (9.2)
Grade 3
>5.0–20× ULN
4 (1.4) 13 (4.5) 15 (2.9) 7 (2.4)
Grade 4
>20× ULN
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AST elevations
Grade 1
>ULN-2.5× ULN
94 (33.5) 105 (36.3) 269 (51.2) 115 (39.4)
Grade 2
>2.5–5× ULN
14 (5.0) 16 (5.5) 29 (5.5) 10 (3.4)
Grade 3
>5.0–20× ULN
1 (0.4) 2 (0.7) 7 (1.3) 3 (1.0)
Grade 4
>20×ULN
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Events that occurred while patients were receiving escape therapy are included in the group in which they occurred.
*Three opportunistic infections occurred during the second year in two patients receiving 8 mg/kg TCZ+MTX and in one patient receiving 8 mg/kg TCZ+placebo. There were two cases of
primary pulmonary tuberculosis: one SAE in the 8 mg/kg TCZ+MTX group in year 1 (case originated from Europe; patient had exposure to a patient with active tuberculosis) and one AE
in a patient in the placebo+MTX group who had an unknown history of tuberculosis and who received escape therapy in year 2.
†The patient in the placebo+MTX group had perforated appendicitis approximately 10 months after starting the study. The patient in the 8 mg/kg TCZ+placebo group had diverticulitis
complicated by GI perforation 18 months after starting treatment.
‡As identified by cirrhosis, fibrosis, hepatic failure and other liver damage-related conditions. Based on standardised Medical Dictionary for Regulatory Activities queries.
AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; MTX, methotrexate; PY, patient-years, SAEs, serious adverse events; TCZ,
tocilizumab; ULN, upper limit of normal.
1283Burmester GR, et al. Ann Rheum Dis 2017;76:1279–1284. doi:10.1136/annrheumdis-2016-210561
Clinical and epidemiological research
group.bmj.com on September 21, 2017 - Published by http://ard.bmj.com/Downloaded from 
8Genentech, South San Francisco, California, USA
9Roche Products Ltd., Welwyn Garden City, UK
Acknowledgements The ﬁrst draft of the manuscript was prepared by the
authors, with professional writing and editorial assistance provided by Jennifer
Adlington, PhD, Sara Duggan, PhD, and Meryl Mandle, who provided writing
services on behalf of F. Hoffmann-La Roche.
Contributors GRB and WFR contributed to the conception and design of the
study. GRB, WFR, RFvV, JK, AR-R and RB contributed to data acquisition. GRB,
WFR, RFvV, JK, AR-R, RB, AK and SD analysed and interpreted the data. GRB, WFR,
JK, AK and SD drafted the manuscript. All authors revised the manuscript critically
for important intellectual content. All authors contributed to, reviewed and approved
the ﬁnal manuscript. All authors agree to be accountable for all aspects of the work
in ensuring that questions related to the accuracy or integrity of any part of the
work are appropriately investigated and resolved.
Funding This study was funded by Roche. Funding for manuscript preparation was
provided by F. Hoffmann-La Roche.
Competing interests GRB has received honoraria from Roche for lectures and
consulting. WFR reports grants and personal fees from Roche outside the submitted
work. RFvV reports grants from Roche during the conduct of the study; grants from
AbbVie, Amgen, BMS, GSK, Pﬁzer, Roche, UCB; and personal fees from AbbVie,
Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pﬁzer,
Roche, UCB, and Vertex outside the submitted work. JK reports grants and personal
fees from AbbVie, Eli Lilly and Company, Genentech, Pﬁzer, Roche Laboratories and
UCB; and personal fees from Amgen, Boehringer Ingelheim GmbH, Bristol-Myers
Squibb Company, Crescendo Bioscience, Epirus Biopharmaceuticals, GlaxoSmithKline,
Hospira, Janssen Biotech, Merck Sharp & Dohme, Novartis Pharmaceuticals,
Regeneron Pharmaceuticals, Samsung Bioepis and Sandoz outside the submitted
work. AR-R reports personal fees from Roche and Chugai during the conduct of the
study and personal fees from Pﬁzer, Lilly, BMS, AbbVie, MSD, UCB, Janssen, Sanoﬁ
and Boehringer outside the submitted work. RB reports grants from Roche, Merck
Sharp & Dohme and AbbVie outside the submitted work. AK is an employee of
Genentech. SD is an employee of Roche Products.
Patient consent Obtained.
Ethics approval This trial was conducted in accordance with the principles of the
Declaration of Helsinki and Good Clinical Practice and was approved by the
Institutional Review Board/Independent Ethics Committee governing each site.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological disease-modifying
antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.
2 Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology
Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res
2016;68:1–25.
3 Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab
improves treatment outcomes in patients with rheumatoid arthritis refractory to
anti-tumour necrosis factor biologicals: results from a 24-week multicentre
randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
4 Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor
inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION
study): a double-blind, placebo-controlled, randomised trial. Lancet
2008;371:987–97.
5 Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with
tocilizumab reduces disease activity in rheumatoid arthritis with inadequate
response to disease-modifying antirheumatic drugs: the tocilizumab in combination
with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum
2008;58:2968–80.
6 Kremer JM, Blanco R, Brzosko S, et al. Tocilizumab inhibits structural joint damage
in rheumatoid arthritis patients with inadequate responses to methotrexate: results
from the double-blind treatment phase of a randomized placebo-controlled trial of
tocilizumab safety and prevention of structural joint damage at one year. Arthritis
Rheum 2011;63:609–21.
7 Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus
methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis:
the AMBITION study. Ann Rheum Dis 2010;69:88–96.
8 Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus
adalimumab monotherapy for treatment of rheumatoid arthritis
(ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet
2013;381:1541–50.
9 Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to
tocilizumab monotherapy in methotrexate inadequate responders: 24-week
symptomatic and structural results of a 2 year randomized controlled strategy trial in
rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43–50.
10 Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive
rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis
2016;75:1081–91.
11 Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classiﬁcation
criteria: an American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
12 Burmester GR, Kivitz AJ, Kupper H, et al. Efﬁcacy and safety of ascending
methotrexate dose in combination with adalimumab: the randomised CONCERTO
trial. Ann Rheum Dis 2015;74:1037–44.
13 Burmester GR, Choy E, Kivitz A, et al. Low immunogenicity of tocilizumab in
patients with rheumatoid arthritis. Ann Rheum Dis 2016; ▪▪▪.
1284 Burmester GR, et al. Ann Rheum Dis 2017;76:1279–1284. doi:10.1136/annrheumdis-2016-210561
Clinical and epidemiological research
group.bmj.com on September 21, 2017 - Published by http://ard.bmj.com/Downloaded from 
placebo-controlled FUNCTION trial
radiographic results from the randomised,
rheumatoid arthritis: 2-year clinical and 
in methotrexate-naive patients with early
monotherapy or methotrexate monotherapy 
Tocilizumab combination therapy or
Dimonaco
Kay, Andrea Rubbert-Roth, Ricardo Blanco, Alysha Kadva and Sophie 
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan
doi: 10.1136/annrheumdis-2016-210561
2017
2017 76: 1279-1284 originally published online April 7,Ann Rheum Dis 
 http://ard.bmj.com/content/76/7/1279
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://ard.bmj.com/content/76/7/1279
This article cites 12 articles, 6 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (628)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 21, 2017 - Published by http://ard.bmj.com/Downloaded from 
